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Background
Cytotoxic CD8+ T lymphocytes (CTL) mediate target
cell killing of tumor cells. New technological advances
in multi-parameter flow cytometry have enabled the
detection and enumeration of antigen-specific CD8+
T cells (MHC-class I dextramer staining) in peripheral
blood. A new dextramer based IVD test has been
approved in Europe for the quantification of CMV spe-
cific CD8 T cells in peripheral blood. However, the fea-
sibility of this type of assay in other relevant sample
types such solid tumors to interrogate tumor-infiltrating
lymphocytes has not yet been established.
Methods
We have developed a dextramer based assay to query
the tumor-infiltrating lymphocyte population in mela-
noma for tumor neoepitope-specific CD8+ T cells.
Through literature evaluation we identified 25 mela-
noma related neopeptides in major HLA subtypes, and
procured the corresponding synthesized dextramer
Amgen Inc., Thousand Oaks, CA, USA
Figure 1 Right: MART-1 specific Dextramer detects CD8+ cell in ELAGIGILTV peptides cultured PBMC isolated from HLA A*0201 subtype.
Q2 region captured CD8+ T/MART-1 specific T Cell, Left: Disaggregates of Melanoma tumor Dextramer straining.
Wang et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P109
http://www.immunotherapyofcancer.org/content/3/S2/P109
© 2015 Wang et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
reagents from Immudex. In addition, control dextramer
reagents against human CMV and HSV1 were also gen-
erated. Assay development also included ensuring that
the enzymatic tumor dissociation and cell preservation
did not disrupt cell surface CD marker epitopes and
TCRs from clipping during tissue processing. We also
incorporated a step in the flow cytometry portion of the
assay to distinguish between viable and non-viable cell
populations and cellular debris, and CD3, CD8 and
CD45 for specific cellular phenotyping. In parallel, high
resolution 4 digit HLA typing information in HLA-A*
and HLA-B* alleles was determined in peripheral blood
from healthy volunteers.
Results
The Dextramer assay was performed in procured
matched melanoma tumor disaggregates and peripheral
blood from five subjects with matched peripheral blood
and their high resolution HLA typing information. The
assay platform established included a live/dead stain
along with CD3, CD8, CD45 to isolate the cell popula-
tion of interest, and then used a set of reagents includes
SSDYVIPIGTY on Tyrosinase; ELAGIGILTV on
MART-1; ITDQVPFSV on gp100 and YLQLVFGIEV on
MAGE-A2 of melanoma related dextramers to identify
antigen-specific CD8+T cells in both peripheral blood
and tumor disaggregate.
Conclusions
We have successfully applied a fit-for-purpose flow cyto-
metry based assay using the dextramer technology to
interrogate melanoma tumor infiltrating lymphocytes.
This assay can be utilized for both immune-oncology
drug developments as well as for monitoring treatment
responses in the clinic.
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